AIMS/HYPOTHESIS: The content of heparan sulphate is reduced in the endothelium under hyperglycaemic conditions and may contribute to the pathogenesis of atherosclerosis. Heparanase-1 (HPR1) specifically degrades heparan sulphate proteoglycans. We therefore sought to determine whether: (1) heparan sulphate reduction in endothelial cells is due to increased HPR1 production through increased reactive oxygen species (ROS) production; and (2) HPR1 production is increased in vivo in endothelial cells under hyperglycaemic and/or atherosclerotic conditions. METHODS: HPR1 mRNA and protein levels in endothelial cells were analysed by RT-PCR and Western blot or HPR1 enzymatic activity assay, respectively. Cell surface heparan sulphate levels were analysed by FACS. HPR1 in the artery from control rats and a rat model of diabetes, and from patients under hyperglycaemic and/or atherosclerotic conditions was immunohistochemically examined. RESULTS: High-glucose-induced HPR1 production and heparan sulphate degradation in three human endothelial cell lines, both of which were blocked by ROS scavengers, glutathione and N-acetylcysteine. Exogenous H(2)O(2) induced HPR1 production, subsequently leading to decreased cell surface heparan sulphate levels. HPR1 content was significantly increased in endothelial cells in the arterial walls of a rat model of diabetes. Clinical studies revealed that HPR1 production was increased in endothelial cells under hyperglycaemic conditions, and in endothelial cells and macrophages in atherosclerotic lesions. CONCLUSIONS/ INTERPRETATION: Hyperglycaemia induces HPR1 production and heparan sulphate degradation in endothelial cells through ROS. HPR1 production is increased in endothelial cells from a rat model of diabetes, and in macrophages in the atherosclerotic lesions of diabetic and non-diabetic patients. Increased HPR1 production may contribute to the pathogenesis and progression of atherosclerosis.
AIMS/HYPOTHESIS: The content of heparan sulphate is reduced in the endothelium under hyperglycaemic conditions and may contribute to the pathogenesis of atherosclerosis. Heparanase-1 (HPR1) specifically degrades heparan sulphate proteoglycans. We therefore sought to determine whether: (1) heparan sulphate reduction in endothelial cells is due to increased HPR1 production through increased reactive oxygen species (ROS) production; and (2) HPR1 production is increased in vivo in endothelial cells under hyperglycaemic and/or atherosclerotic conditions. METHODS:HPR1 mRNA and protein levels in endothelial cells were analysed by RT-PCR and Western blot or HPR1 enzymatic activity assay, respectively. Cell surface heparan sulphate levels were analysed by FACS. HPR1 in the artery from control rats and a rat model of diabetes, and from patients under hyperglycaemic and/or atherosclerotic conditions was immunohistochemically examined. RESULTS: High-glucose-induced HPR1 production and heparan sulphate degradation in three human endothelial cell lines, both of which were blocked by ROS scavengers, glutathione and N-acetylcysteine. Exogenous H(2)O(2) induced HPR1 production, subsequently leading to decreased cell surface heparan sulphate levels. HPR1 content was significantly increased in endothelial cells in the arterial walls of a rat model of diabetes. Clinical studies revealed that HPR1 production was increased in endothelial cells under hyperglycaemic conditions, and in endothelial cells and macrophages in atherosclerotic lesions. CONCLUSIONS/ INTERPRETATION: Hyperglycaemia induces HPR1 production and heparan sulphate degradation in endothelial cells through ROS. HPR1 production is increased in endothelial cells from a rat model of diabetes, and in macrophages in the atherosclerotic lesions of diabetic and non-diabeticpatients. Increased HPR1 production may contribute to the pathogenesis and progression of atherosclerosis.
Authors: Mabel J van den Hoven; Femke Waanders; Angelique L Rops; Andrea B Kramer; Harry van Goor; Jo H Berden; Gerjan Navis; Johan van der Vlag Journal: Nephrol Dial Transplant Date: 2009-05-09 Impact factor: 5.992
Authors: T J M Wijnhoven; M J W van den Hoven; H Ding; T H van Kuppevelt; J van der Vlag; J H M Berden; R A Prinz; E J Lewis; M Schwartz; X Xu Journal: Diabetologia Date: 2007-12-06 Impact factor: 10.122
Authors: Iris J Edwards; Janice D Wagner; Catherine A Vogl-Willis; Kenneth N Litwak; William T Cefalu Journal: Cardiovasc Diabetol Date: 2004-04-29 Impact factor: 9.951
Authors: Eric P Schmidt; Yimu Yang; William J Janssen; Aneta Gandjeva; Mario J Perez; Lea Barthel; Rachel L Zemans; Joel C Bowman; Dan E Koyanagi; Zulma X Yunt; Lynelle P Smith; Sara S Cheng; Katherine H Overdier; Kathy R Thompson; Mark W Geraci; Ivor S Douglas; David B Pearse; Rubin M Tuder Journal: Nat Med Date: 2012-07-22 Impact factor: 53.440
Authors: Rowan F van Golen; Megan J Reiniers; Nienke Vrisekoop; Coert J Zuurbier; Pim B Olthof; Jacco van Rheenen; Thomas M van Gulik; Barry J Parsons; Michal Heger Journal: Antioxid Redox Signal Date: 2014-02-19 Impact factor: 8.401